Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204941 | 0.84 | HTR2C (0.53) | HTR2AHTR2CMAPTRXFP1SLC6A2 | |
| SCHEMBL9910664 | 0.82 | HTR2A (0.47) | HTR2AHTR2CMAPTRXFP1SLC6A2 | |
| SCHEMBL13974042 | 0.82 | HTR2A (0.51) | HTR2AHTR2CMAPTRXFP1SLC6A2 | |
| SCHEMBL15024791 | 0.79 | BRD4 (0.51) | HTR2AHTR2CMAPTRXFP1SLC6A2 | |
| SCHEMBL13980998 | 0.79 | HTR2A (0.45) | HTR2AHTR2CMAPTRXFP1SLC6A2 | |
| SCHEMBL6258605 | 0.79 | HTR2A (0.45) | HTR2AHTR2CMAPTRXFP1SLC6A2 | |
| SCHEMBL21244767 | 0.78 | KDM4E (0.39) | HTR2AHTR2CSLC6A2SLC6A4CYP2A6 | |
| SCHEMBL21244778 | 0.78 | BRD4 (0.36) | HTR2AHTR2CMAPTSLC6A2SLC6A4 | |
| SCHEMBL21140435 | 0.78 | BRD4 (0.36) | HTR2AHTR2CSLC6A2SLC6A4CYP2A6 | |
| SCHEMBL20365098 | 0.78 | HTR2C (0.54) | HTR2AHTR2CSLC6A2SLC6A4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV INDIANA TRUSTEES (US) | 2023-04-20 | — | — | US | disclosed |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022123530-A1 | BORONIC ACID COMPOUND | 주식회사 엘지화학 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022107144-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-05-27 | — | — | WO | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210070784-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-03-11 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070784-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | HTR2A 3684/4885HTR2C 4111/4885MAPT 920/4885 |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | AZI2, GPR119, GID4 | HTR2A 77/4885HTR2C 81/4885MAPT 3350/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | HTR2A 3755/4885HTR2C 3949/4885MAPT 1544/4885 |
| US-20230124268-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | NAMPT, NNT, NAPRT | HTR2A 3684/4885HTR2C 4111/4885MAPT 920/4885 |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | HTR2C, HTR3A, HTR3C | HTR2A 9/4885HTR2C 1/4885MAPT 4260/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | HTR2A 4079/4885HTR2C 4559/4885MAPT 2590/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | HTR2A 4866/4885HTR2C 4731/4885MAPT 1399/4885 |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | NT5C3B, DERA, DUT | HTR2A 2010/4885HTR2C 2804/4885MAPT 4669/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTR2A 4866/4885HTR2C 4731/4885MAPT 1399/4885 |
| US-11584766-B2 | Nicotinamide phosphoribosyltransferase inhibitors and methods for use of the same | NAMPT, NNT, NAPRT | HTR2A 3684/4885HTR2C 4111/4885MAPT 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.